Drug Profile


Alternative Names: BIRR 4; sICAM; sICAM-rhinovirus; soluble ICAM-1; tremacamra

Latest Information Update: 08 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Isis Pharmaceuticals
  • Class Antivirals; Glycoproteins
  • Mechanism of Action Immunomodulators; Virus attachment inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV-1 infections
  • Discontinued Diabetes mellitus; Rhinovirus infections

Most Recent Events

  • 08 May 2003 Discontinued - Preclinical for Diabetes mellitus in Germany (unspecified route)
  • 29 Sep 2000 Discontinued-II for Rhinovirus infections in USA (Intranasal)
  • 29 Sep 2000 Discontinued-Preclinical for Rhinovirus infections in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top